Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Type 2 diabetes mellitus is a metabolic disorder that is primarily characterized by insulin
resistance, relative insulin deficiency, and hyperglycemia. People with type 2 diabetes are
at high risk of many serious diabetic complications, including cardiovascular disease,
blindness, nerve damage and kidney damage. Balaglitazone is a thiazolidinedione derivative
that is being developed as an oral anti-diabetic drug to improve blood glucose control in
patients with type 2 diabetes. The purpose of this study is to assess if additional treatment
with balaglitazone in patients with type 2 diabetes on stable insulin treatment will improve
blood glucose control and decrease the daily insulin dose compared to placebo, but with less
impact on weight gain and oedema than pioglitazone (Actos®) 45 mg.